{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:10:52Z","timestamp":1791051052202,"version":"4.1.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1991,4,1]],"date-time":"1991-04-01T00:00:00Z","timestamp":670464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1991,4]]},"abstract":"<jats:p>A series of novel compounds, 5-alkynyl-1-beta-D-ribofuranosylimidazole-4- carboxamides, have been identified as broad-spectrum antiviral agents. 5-Ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide (EICAR), the most potent congener of the group, showed antiviral potency about 10- to 100-fold greater than that of ribavirin. Similar in spectrum to ribavirin, EICAR was particularly active (50% inhibitory concentration, 0.2 to 4 micrograms\/ml) against poxviruses (vaccinia virus), togaviruses (Sindbis and Semliki forest viruses), arenaviruses (Junin and Tacaribe viruses), reoviruses (reovirus type 1), orthomyxoviruses (influenza A and B viruses), and paramyxoviruses (parainfluenza virus type 3, measles virus, subacute sclerosing panencephalitis virus, and respiratory syncytial virus). EICAR was also cytostatic for rapidly growing cells (50% inhibitory concentration, 0.2 to 0.9 microgram\/ml). EICAR inhibited vaccinia virus tail lesion formation at doses that were not toxic to the host. EICAR is a candidate antiviral drug for the treatment of pox-, toga-, arena-, reo-, orthomyxo, and paramyxovirus infections.<\/jats:p>","DOI":"10.1128\/aac.35.4.679","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T20:05:50Z","timestamp":1340827550000},"page":"679-684","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":108,"title":["Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds"],"prefix":"10.1128","volume":"35","author":[{"given":"E","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cools","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Balzarini","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Andrei","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hosoya","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Shigeta","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ueda","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Minakawa","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.35.4.679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.35.4.679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:18:51Z","timestamp":1645438731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.35.4.679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1991,4]]}},"alternative-id":["10.1128\/AAC.35.4.679"],"URL":"https:\/\/doi.org\/10.1128\/aac.35.4.679","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,4]]},"assertion":[{"value":"1991-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}